- A place on one of the UK’s biggest business stages: Chief Strategy & Business Officer Tara Lumley joined the ‘Your First 100 Customers’ panel at Ideas Fest, which brought together more than 6,000 business leaders across 500+ sessions.
- From clinical research to everyday use: Tara shared what Klario®’s first 100 customers taught the team: who was buying, how they were using Klario, and what the company changed as a result.
- Trust as a commercial foundation: The session also explored what it really takes to build trust with a community, both before and after they become customers.
London, UK – Flow Health Science, the London-based advanced nutrition company behind Klario®, took part in Ideas Fest 2026, with Chief Strategy & Business Officer Tara Lumley speaking on the ‘Your First 100 Customers’ panel alongside founders from across the consumer landscape.
Klario is a first-in-class hypoglycaemia recovery drink for people living with diabetes, built on a proprietary MESH™ formulation. In a randomised clinical study analysing more than 1,000 hypoglycaemic episodes, published in Diabetes, Obesity and Metabolism, Klario was associated with a 27% reduction in recurrent hypoglycaemia compared with standard glucose-only products.
Since launching in the UK, Flow Health Science has heard from hundreds of customers about how Klario is changing the way they manage hypos in daily life. On the panel, Tara drew on that early commercial experience to discuss the realities of taking a product from clinical research into the hands of people living with type 1 diabetes: who the earliest customers were, how they used Klario in practice, and how their feedback shaped the company’s decisions.
Tara also reflected on the role of trust in an underserved health category, where clinical evidence is essential but community relationships matter just as much, both before someone buys and long after.
Off-stage, the team exchanged ideas with investors, founders and creators across food, consumer health and finance.
“Seeing Klario used in real life is incredibly rewarding. Our early customers helped us understand what it takes to turn science into a product people can trust, and their insights continue to shape what comes next.” — Tara Lumley, Chief Strategy & Business Officer, Flow Health Science
About the Product
Klario®: A Novel Approach to Hypoglycaemia Management
Hypoglycemia represents a critical therapeutic challenge in diabetes management: people with T1D may experience 100–200 treatment-related episodes annually. Current recommended therapeutic interventions using glucose-only treatments frequently result in suboptimal outcomes, including rapid glucose fluctuations, persistent neuroglycopenic symptoms, and fear-driven non-adherence to medication. Klario, a novel multi-substrate energy formulation combining glucose with BHB, was designed to achieve more complete recovery from hypoglycemia. In line with medical guidelines, Klario delivers 15 grams of fast-acting carbs to raise blood glucose quickly, while also raising BHB levels acutely. This combination formula improves glycemic control in the immediate post-treatment period and provides rapid, sustained neuroglycopenic recovery. For more information about Klario, please visit myklario.com.
About Flow Health Science
Flow Health Science is dedicated to transforming health outcomes through trusted, clinically-proven functional foods. Grounded in advanced metabolic science, our research and pipeline targets diabetes management, fatigue, hormone imbalances, and broader metabolic dysfunction.
Media Contact: Tara Lumley, Chief Strategy & Business Officer — press@flowhealthscience.com
Source: Flow Health Science